Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arikayce in Cystic Fibrosis with Pseudomonas Aeruginosa
NCT01315678Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Feb 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of amikacin liposome inhalation suspension in cystic fibrosis (CF) and Pseudomonas aeruginosa infection (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Forced Expiratory Volume in 1 Second. Started Feb 2012; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT01315678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315678.